PDZK1 disassembles HER2-HSP90 complexes to promote ubiquitin-mediated HER2 degradation and overcome therapy resistance
{{output}}
Introduction: Limited therapeutic response and disease recurrence remain major challenges in HER2-positive breast cancer, largely driven by sustained HER2 stabilization and persistent oncogenic signaling mediated by HSP90. Theref... ...
